Photo: Prasit photo/Getty Images
The Trump administration is expected to announce the launch of TrumpRx, a marketplace that allows consumers to purchase drugs directly through the government instead of through insurance at a discounted price.
The White House has also announced that it has brokered a deal with Pfizer to lower the price of many prescription medications in the U.S.
The direct-to-consumer government website will allow individuals to pay cash for certain drugs at discounted prices that have been negotiated by the government, according to reporting from the Wall Street Journal.
The marketplace, TrumpRx, will be operated by the federal government and will include numerous drugs by pharma giant Pfizer.
The deal with Pfizer will see lower drug prices that are in line with the lowest paid by other developed nations, according to the White House.
"The agreement will provide every State Medicaid program in the country access to MFN [most-favored-nation] drug prices on Pfizer products, resulting in many millions of dollars in savings and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable," the White House said.
"The agreement requires Pfizer to repatriate increased foreign revenue on existing products that Pfizer realizes as a result of the President’s strong America First U.S. trade policies for the benefit of American patients."
Additionally, the deal will require Pfizer to offer medications at a deep discount when selling directly to American patients.
The drugs to be offered at lower costs include Eucrisa, a topical ointment for atopic dermatitis. The medication will be made available at an 80% discount to patients purchasing directly.
Xeljanz, an oral medication for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, will be available at a 40% discount, and Zavzpret, a drug for treating migraines, will be sold directly to consumers at a 50% discount.
According to media reports, the deal will give Pfizer a three-year grace period on Trump’s tariffs on pharmaceutical drugs made overseas, which are expected to take effect Oct. 1.
In July, Press Secretary Karoline Leavitt shared a post on X where she read a letter Trump sent to 17 pharmaceutical companies demanding drug prices be reduced, with a deadline to respond to the letter by Sept. 29.
The White House said it expects other pharmaceutical companies to follow in Pfizer's steps.
